Since RAS/MAPK pathway-associated genomic alterations are common in LEATs [24] and that the BRAF V600E mutation has been identified in 20–60% and 30% of gangliogliomas and DNTs, respectively [2, 26], there is a possibility that the BRAF V600E mutation and MAPK pathway-related genomic alterations may activate methionine metabolism in LEATs. This evidence concerns the gene BRAF and ganglioglioma.